New drugs and other strategies for the treatment of fungal infections

References

• 1. Qadri H, Shah AH, Mir M. Novel strategies to combat the emerging drug resistance in human pathogenic microbes. Curr. Drug Targets 22(12), 1424–1436 (2021).
  Medline CASGoogle Scholar
• 2. Rodrigues ML, Nosanchuk JD. Fungal diseases as neglected pathogens: a wake-up call to public health officials. PLoS Negl. Trop. Dis. 14(2), e0007964 (2020).
  MedlineGoogle Scholar
• 3. Hoenigl M, Sprute R, Egger M et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs 81(15), 1703–1729 (2021).
  Medline CASGoogle Scholar
• 4. Aggarwal R, Targhotra M, Kumar B, Sahoo PK, Chauhan MK. Treatment and management strategies of onychomycosis. J. Mycol. Med. 30(2), 100949 (2020).
  Medline CASGoogle Scholar
• 5. Iyer KR, Revie NM, Fu C, Robbins N, Cowen LE. Treatment strategies for cryptococcal infection: challenges, advances and future outlook. Nat. Rev. Microbiol. 19(7), 454–466 (2021).
  Medline CASGoogle Scholar
• 6. Carpouron JE, de Hoog S, Gentekaki E, Hyde KD. Emerging animal-associated fungal diseases. J. Fungi. (Basel) 8(6), 611 (2022).
  MedlineGoogle Scholar
• 7. Chaves AFA, Xander P, Romera LMD, Fonseca FLA, Batista WL. What is the elephant in the room when considering new therapies for fungal diseases? Crit. Rev. Microbiol. 47(3), 275–289 (2021).
  MedlineGoogle Scholar
• 8. Curto MÁ, Butassi E, Ribas JC, Svetaz LA, Cortés JCG. Natural products targeting the synthesis of β(1,3)-D-glucan and chitin of the fungal cell wall. Existing drugs and recent findings. Phytomedicine 88, 153556 (2021).
  Medline CASGoogle Scholar
• 9. Almeida MA, Bernardes-Engemann AR, Coelho RA et al. Mebendazole inhibits histoplasma capsulatum in vitro growth and decreases mitochondrion and cytoskeleton protein levels. J. Fungi. (Basel) 9(3), 385 (2023).
  Medline CASGoogle Scholar
• 10. Campoy S, Adrio JL. Antifungals. Biochem. Pharmacol. 133, 86–96 (2017).
  Medline CASGoogle Scholar
• 11. Souza ACO, Amaral AC. Antifungal therapy for systemic mycosis and the nanobiotechnology era: improving efficacy, biodistribution and toxicity. Front Microbiol. 8, 336 (2017).
  MedlineGoogle Scholar
• 12. Su S, Yan H, Min L et al. The antifungal activity of caspofungin in combination with antifungals or non-antifungals against Candida species in vitro and in clinical therapy. Expert Rev. Anti. Infect. Ther. 20(2), 161–178 (2022).
  Medline CASGoogle Scholar
• 13. Zhang J, Lin P, Li J, Guo C, Zhai J, Zhang Y. Efficacy of laser therapy combined with topical antifungal agents for onychomycosis: a systematic review and meta-analysis of randomised controlled trials. Lasers Med. Sci. 37(6), 2557–2569 (2022).
  MedlineGoogle Scholar
• 14. Kokoska L, Kloucek P, Leuner O, Novy P. Plant-derived products as antibacterial and antifungal agents in human health care. Curr. Med. Chem. 26(29), 5501–5541 (2019).
  Medline CASGoogle Scholar
• 15. Passero LFD, Cavallone IN, Belda W. Reviewing the etiologic agents, microbe-host relationship, immune response, diagnosis, and treatment in chromoblastomycosis. J. Immunol. Res. 2021, 9742832 (2021).
  MedlineGoogle Scholar
• 16. Candel FJ, Peñuelas M, Tabares C et al. Fungal infections following treatment with monoclonal antibodies and other immunomodulatory therapies. Rev. Iberoam. Micol. 37(1), 5–16 (2020).
  MedlineGoogle Scholar
• 17. Teixeira MM, Almeida-Paes R, Bernardes-Engemann AR et al. Single nucleotide polymorphisms and chromosomal copy number variation may impact the Sporothrix brasiliensis antifungal susceptibility and sporotrichosis clinical outcomes. Fungal Genet Biol. 163, 103743 (2022).
  Medline CASGoogle Scholar
• 18. Shishodia SK, Tiwari S, Shankar J. Resistance mechanism and proteins in Aspergillus species against antifungal agents. Mycology 10(3), 151–165 (2019).
  Medline CASGoogle Scholar
• 19. Silva DR, Sardi J de CO, Freires IA, Silva ACB, Rosalen PL. In silico approaches for screening molecular targets in Candida albicans: a proteomic insight into drug discovery and development. Eur. J. Pharmacol. 842, 64–69 (2019).
  Medline CASGoogle Scholar